Overview

Study of Sulphoraphane in Chronic Kidney Disease

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the compound sulforaphane that boosts the activity of antioxidant genes in the body to combat oxidative stress. Oxidative stress has been shown experimentally to play a role in kidney disease. This drug has been tested in patients with breast cancer who have normal kidney function, but has never been tested in patients with kidney disease. In this study, the investigators will establish a safe dose for patients with chronic kidney disease based on blood levels achieved in patients with normal kidney function.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
National Institutes of Health (NIH)
Treatments:
Sulforaphane